Observational Multicenter Study in Ex-People Who INject Drugs (Ex-PWIDs) to Evaluate Efficacy, Safety, and Adherence to TElaprevir in Combination With Pegylated Interferon Alfa and Ribavirin in Genotype 1 ChRonic HepATitis C PatiEnts
Phase of Trial: Phase IV
Latest Information Update: 01 Jun 2017
Price : $35 *
At a glance
- Drugs Telaprevir (Primary) ; Peginterferon alfa-2a; Peginterferon alfa-2b; Ribavirin
- Indications Hepatitis C
- Focus Therapeutic Use
- Acronyms INTEGRATE
- Sponsors Janssen Pharmaceutica
- 01 Jun 2017 Results published in the Infectious Diseases and Therapy.
- 08 Mar 2015 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 20 Jan 2015 Planned End Date changed from 1 Mar 2015 to 1 Jan 2015 as reported by ClinicalTrials.gov.